The High Cost of Insulin in the United States: An Urgent Call to Action

被引：35
作者：
Rajkumar, S. Vincent [1 ]
机构：
[1] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
MAYO CLINIC PROCEEDINGS | 2020年 / 95卷 / 01期
关键词：
AFFORDABILITY;
D O I：
10.1016/j.mayocp.2019.11.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：22 / 28
页数：7
相关论文
共 35 条
[1]  
Amin T, PATENT ABUSE IS DRIV
[2]  
Anderson Gerard F., 2019, Health Affairs Blog, DOI [DOI 10.1377/HBLOG20190715.557473/FULL/, DOI 10.1377/HBLOG20190715.557473/FULL]
[3]  
[Anonymous], AM J MED
[4]   Insulin Access and Affordability Working Group: Conclusions and Recommendations [J].
Cefalu, William T. ;
Dawes, Daniel E. ;
Gavlak, Gina ;
Goldman, Dana ;
Herman, William H. ;
Van Nuys, Karen ;
Powers, Alvin C. ;
Taylor, Simeon I. ;
Yatvin, Alan L. .
DIABETES CARE, 2018, 41 (06) :1299-1311
[5]  
Cohen M, POLICY OPTIONS INCRE, DOI [10.1377/hblog20190103.333047/full/, DOI 10.1377/HBLOG20190103.333047/FULL/]
[6]   Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices [J].
Dusetzina, Stacie B. ;
Keating, Nancy L. ;
Huskamp, Haiden A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (15) :1401-1404
[7]   Association of Prescription Drug Price Rebates inMedicare Part D With Patient Out-of-Pocket and Federal Spending [J].
Dusetzina, Stacie B. ;
Conti, Rena M. ;
Yu, Nancy L. ;
Bach, Peter B. .
JAMA INTERNAL MEDICINE, 2017, 177 (08) :1185-1188
[8]   Medicare Spending and Potential Savings on Brand-name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015 [J].
Egilman, Alexander C. ;
Wallach, Joshua D. ;
Ross, Joseph S. ;
Dhruva, Sanket S. .
JAMA INTERNAL MEDICINE, 2018, 178 (04) :567-+
[9]  
Fein AJ, BIG 3 WHOLESALERS RE
[10]  
Fein AJ, CVS EXPRESS SCRIPTS
1234